PRDM16 Protein Fights Cellular Aging by Activating a Key Antioxidant Gene
Scientists discover PRDM16 declines in aged organs and its loss accelerates senescence; restoring it via GSTM1 may slow organ aging.
Summary
Researchers at Huazhong University found that PRDM16, a transcriptional regulator, drops significantly in aged organs of mice and humans. When PRDM16 is genetically deleted in mice, senescence markers surge across kidneys, heart, lungs, brain, stomach, and gut—and aging-related organ damage worsens. Conversely, restoring PRDM16 via lentiviral delivery reduces cellular senescence both in cell culture and in living animals. Mechanistically, PRDM16 binds directly to the promoter of GSTM1—a glutathione S-transferase enzyme—boosting glutathione metabolism and shielding DNA from oxidative damage, a primary driver of senescence. The findings point to the PRDM16–GSTM1 axis as a promising therapeutic target for combating age-related diseases.
Detailed Summary
Cellular senescence—the state in which damaged cells stop dividing but refuse to die—accumulates with age and drives chronic inflammation, fibrosis, and organ decline through the senescence-associated secretory phenotype (SASP). Despite intense interest in senolytics and senomorphics, the transcriptional regulators that govern whether cells enter senescence remain incompletely understood. This study addresses that gap by identifying PRDM16 as a critical anti-senescence factor.
The researchers first screened all PRDM family members across kidneys, lungs, heart, and stomach of young (2-month) versus aged (24-month) mice. PRDM16 was the only family member consistently and significantly downregulated across all organs tested. This pattern was validated in human datasets: PRDM16 mRNA in renal cortex negatively correlated with age (NephroSeq, n=71), and similar inverse age relationships were found in heart, hippocampus, and lung transcriptomes from the ADEIP platform. In human lung tissue, PRDM16 expression also inversely correlated with the senescence marker CDKN1A. In vitro, PRDM16 was reduced in HK-2 (kidney), Beas-2B (lung), and H9C2 (cardiac) cells made senescent by X-ray irradiation, bleomycin, or doxorubicin.
To establish causality, the team generated global Prdm16 knockout (KO) mice. Even at 3 weeks of age, KO mice showed elevated senescence markers (p21/CDKN1A, p16/CDKN2A, Tp53) and SASP genes (Il6, Il1b, Tnf, Tgfb1) across six organs. By 9 months, serum SASP cytokines—including IL-1β, CCL2, IL-6, G-CSF, and CCL4—were markedly elevated. Single-cell RNA sequencing of kidneys from 9-month KO mice revealed enrichment of DNA damage response genes across multiple cell types including proximal and distal tubule cells, endothelial cells, macrophages, and stromal cells. Tubule-specific Prdm16 deletion further exacerbated irradiation-induced kidney aging and worsened outcomes after ischemia-reperfusion injury. Lentiviral PRDM16 overexpression attenuated senescence markers both in cultured cells and in irradiated mouse kidneys in vivo.
Mechanistically, RNA sequencing and metabolomic profiling showed that PRDM16 deficiency impairs glutathione metabolism, elevating reactive oxygen species (ROS) and oxidative DNA damage (measured by 8-OHdG and γH2AX). Chromatin immunoprecipitation (ChIP) assays confirmed that PRDM16 directly binds the promoter of GSTM1, a mu-class glutathione S-transferase that detoxifies ROS-generating electrophiles. Overexpression of GSTM1 rescued PRDM16-deficiency-induced senescence in cells, while GSTM1 knockdown abolished the protective effects of PRDM16 restoration. This PRDM16→GSTM1→glutathione→reduced oxidative DNA damage→reduced senescence axis was consistently validated across multiple models.
The study establishes PRDM16 as a previously unrecognized suppressor of cellular senescence operating through an antioxidant transcriptional program. Its broad expression across organs and consistent decline with aging make it an attractive target for interventions aimed at compressing morbidity in aging-related diseases, particularly kidney disease.
Key Findings
- PRDM16 is the only PRDM family member consistently downregulated across multiple aged organs in mice and humans.
- Global Prdm16 knockout accelerates senescence markers and SASP cytokines across six organ systems, even in young mice.
- Tubule-specific Prdm16 deletion worsens irradiation-induced kidney aging and ischemia-reperfusion injury outcomes.
- PRDM16 directly binds the GSTM1 promoter, upregulating glutathione metabolism and reducing oxidative DNA damage.
- Lentiviral PRDM16 restoration and GSTM1 overexpression both reverse senescence phenotypes in vitro and in vivo.
Methodology
The study used global and tubule-specific Prdm16 knockout mouse models, lentiviral gene delivery, single-cell RNA sequencing, ChIP assays, metabolomics, and multiple in vitro senescence models (irradiation, bleomycin, doxorubicin, D-galactose) across kidney, lung, and cardiac cell lines. Human validation leveraged NephroSeq renal cortex transcriptomic data (n=71) and the ADEIP multi-organ aging transcriptome platform.
Study Limitations
The study relies heavily on mouse models and cell lines; direct therapeutic translation requires human clinical validation. Lentiviral delivery of PRDM16 is not yet clinically feasible at scale, and long-term safety of PRDM16 overexpression (given its roles in fat browning and hematopoiesis) was not assessed. The liver was notably excluded from the age-related PRDM16 decline pattern, suggesting tissue-specific regulatory differences that need further study.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.